Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 14th Mar 2013 07:11

Amara Mining: After having been under review, Cantor Fitzgerald reinitiates coverage with a price target of 81p and a buy recommendation.Antofagasta: Citigroup shifts target price from 990p to 1000p, but retains its sell recommendation.Ashtead Group: Investec raises target price from 475p to 700p keeping its buy recommendation.AstraZaneca: Exane BNP ups target price from 3000p to 3100p and reiterates a neutral rating.AZ Electronic Minerlas: Liberum Capital initiates with a target price of 440p and a buy recommendation.Barclays: Oriel Securities upgrades to buy with a target price of 380p.Booker Group: Investec places its target price (prev.: 108p) under review and maintains a hold recommendation.British Land: Deutsche Bank cuts target price from 390p to 370p leaving its buy recommendation unaltered.Clarkson: JP Morgan takes target price from 1400p to 1470p, but downgrades to neutral.Clean Air Power: N+1 Singer initiates with a target price of 12p and a buy recommendation.Computacenter: JP Morgan increases target price from 440p to 525p keeping an overweight rating.easyJet: UBS takes target price from 1000p to 1175p reiterating a buy recommendation.EMIS Group: N+1 Singer upgrades to buy with a target price of 780p.Faroe Petroleum: HSBC initiates with a target price of 200p and an overweight rating. Liberum Capital starts with a target price of 198p and a buy recommendation.Ferrexpo: Deutsche Bank lowers target price from 390p to 370p, while maintaining a buy recommendation. JP Morgan reduces target price from 269p to 221p and reiterates an overweight rating.G4S: Jefferies raises target price from 275p to 340p and keeps its buy recommendation. Exane BNP moves target price from 295p to 330p, while its outperform rating remains unchanged. Panmure Gordon ups target price from 320p to 340p maintaining a buy recommendation.Hikma: UBS ups target price from 755p to 805p, but stays with its sell recommendation.Hochschild Mining: JP Morgan cuts target price from 450p to 365p, while its neutral rating remains unchanged.Home Retail: Cantor Fitzgerald shifts target price from 115p to 125p keeping a hold recommendation.HSBC Holdings: Oriel Securities upgrades to buy with a target price of 860p.IG Group Holdings: Citigroup takes target price from 500p to 625p, while leaving its buy recommendation unchanged.IMI: Investec increases target price from 1245p to 1355p, but downgrades from buy to hold.Inchcape: Espirito Santo ups target price from 460p to 510p, but downgrades to neutral.Intu Properties: UBS lowers target price from 365p to 345p and maintains a neutral rating.Legal & General Group: Barclays moves target price from 166.40p to 180.80p and reiterates an overweight rating.Lloyds Banking Group: Oriel Securities downgrades to sell with a target price of 41p.Meggitt: Citigroup increases target price from 450p to 500p, but downgrades to neutral.MITIE Group: oriel Securities downgrades to hold with a target price of 315p.Perform Group: UBS takes taregt price from 425p to 490p, while its buy recommendation is kept.Playtech: Investec raises target price from 400p to 600p and keeps a hold recommendation.Publishing Technology: Westhouse Securities raises target price from 260p to 360p and keeps a buy recommendation.Regenersis: Panmure Gordon takes target price from 206p to 240p and reiterates its buy recommendation.Royal Bank of Scotland: Oriel Securities downgrades to sell with a target price of 245p.RPS Group: Investec revises target price from 275p to 310p keeping a buy recommendation.Smith News: Liberum Capital takes target price from 170p to 188p, while its buy recommendation remains unchanged.Software Radio Technology: WH Ireland shifts target price from 31.50p to 34p and keeps a buy recommendation.Standard Chartered: Oriel Securities downgrades to add with a target price of 2050p.St Ives: N+1 Singer raises target price from 159p to 172p and maintains a buy recommendation.Thomas Cook Group: Morgan Stanley ups target price from 100p to 150p maintaining an overweight rating. UBS revises target price from 100p to 125p, while staying with its buy recommendation. Exane BNP shifts target price from 70p to 75p and retains an underperform rating. HSBC increases target price from 100p to 130p and keeps an overweight rating.Visuvius: UBS raises target price from 315p to 375p and retains a neutral rating.
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.